The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Dumbpunter
Take a look at this. It illustrates the situation more clearly:
https://www.lse.co.uk/rns/SNG/holdings-in-company-b263d0ezavkdzpz.html
Doc83 - "Let's have a little BB vote to see what the majority think on here."
The majority has spoken.
I know it's a leap but I'm going to assume none of the people voting there are the company's Communications Director.
Doc83 - "...deserves for the CEO to show his face, to let everyone know they are still around and committed to the cause"
What a ridiculous reason to be throwing a tantrum.
Hopefully we won't hear a peep from them until they've got something meaningful to report. Because we know for certain they will before long.
MrCosts - "How much data do they need..."
Enough positive data for approval. That's a really weird question from someone who's been invested in a drug development firm for over 18 months.
Doc83 - " I can't believe some on here think... RM shouldn't address shareholders"
The only ones crying out for another statement from the company are the people who don't seem to grasp what's happening. To put it another way: when there's more to say, they'll say it.
I could be reading it wrong but it looks like Abramovich just moved the stock to a different company, presumably to keep it out of the reach of any sanctions.
https://www.londonstockexchange.com/news-article/VLS/holding-s-in-company/15348334
sativa - "That is the reality."
No it's not. They can't update some shareholder but not others.
Dumbpunter - "Polygon aren't adding, the shares are in nominee accounts. This indicates small shareholders are nuking not Polygon"
I think you're completely mistaken there.
Everyone should verify this themselves as I'm not an expert and it's not advice. But I'm quite certain that the nominee accounts are where the shares are held on behalf of their owners. Since JP Morgan and Aurora are clearly the nominee accounts, that implies they're holding the shares on behalf of their actual owner, Polygon.
I can provide a clearer example if anyone want to argue it.
I'm not sure what you expect them to say. All we needed to know was in last week's RNS.
When they get more data we'll get another update.
Adrian_london - "What was the reason for the massive drop in share price?"
I assume you're new at investing.
Near the top of the screen you'll see a link that says "SNG Live RNS". Click it and you'll see there was some news released on Monday 21st Feb, the same day the price dropped from 175 to 30p. Have a read through it and you'll see why that happened.
JimSanchez
Dexamethesone was approved by the EMA in mid September 2020, but I don't know how long it would've been before it became the standard treatment all patients would receive. So I still think improved SOC and widespread vaccination is the most likely explanation.
JimSanchez - "how could we have been on track for significant results on the primary endpoints at halfway, given the results we’ve seen from the full cohort? "
I assume improved SOC and widespread vaccinations would explain it.
Manifesto
Not really. That's quite a compliment though.
Ndn71 - "pretty sure that isn’t a serious question, so I won’t bother answering it"
No, it was a serious question.
Normally when you share your opinion on here it's poorly thought out and I usually disagree with you. So I wondered if that was the exception.
Ndn - "Then bottom-drawer until readout - same risk, much reduced reward"
Why do you think the reward will be reduced? If it works, the market potential is still the same as before.
TLWilliams
I'm aware of, and have considered everything you wrote there. But you haven't explained why you think a potential buyer would pass up the chance to build a stake at 30p but then put in an offer of "many multiples of 30p".
It really is. I hadn't noticed that. Thanks Owl.
TLWilliams - "30p is the distressed price as a consequence of the outcome of a flawed trial."
I know. It's also the current price. So if anyone was seriously considering a bid, why wouldn't they be accumulating now?
What I'm trying to say is that I don't think there's any real possibility Polygon is buying in anticipation of a reasonable offer.
Why would they offer more than 50p when they could be building a sizeable stake right now for 30p?
Amers - "that most of the money may be gone for while."
I think that's an understatement. I don't see us getting close to £1 until Activ-2 phase 3 is done and close to announceing its results, and it hasn't even started yet.